Tenaya Therapeutics Inc (TNYA) Unusual Options Activity Today

Checking TNYA unusual options activity helps you spot when traders are making outsized bets on Tenaya Therapeutics Inc before the broader market catches on. Tenaya Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor TNYA unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching TNYA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking TNYA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and TNYA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and TNYA unusual options activity is often where that footprint shows up first. Our scanner tracks Tenaya Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at TNYA unusual options volume on the call side or chasing put sweeps, Tenaya Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.